Program Details

Biostatistics for Lawyers

Content Partner:  Celesq AttorneysEd Center
Price: $226.00*
This program is no longer available.

* Applicable Membership or Subscription discounts will be added in your shopping cart

Description: The course will provide a broad overview of key topics in biostatistics that are frequently at the forefront of litigation involving drugs and medical devices. The course will include a review of basic concepts including relative risks, odds ratios, statistical significance and power, comparing proportions, survival analysis, Bayesian analysis, metanalysis, and common issues in trial clinical conduct. The course will also touch on how these concepts figure into judicial opinions. Participants will learn to identify common red flags and pit falls in statistical analysis, develop tools to more effectively conduct discovery and interface with experts, and develop a sense for how courts view and understand these issues.
Abe Alexander practices out of the New York office New York office of Bernstein Litowitz Berger & Grossmann LLP, where he focuses on securities fraud, corporate governance and shareholder rights litigation.
As a principal member of the trial team prosecuting In re Merck Vioxx Securities Litigation, Abe helped recover over $1.06 billion on behalf of injured investors.  The case, which asserted claims arising out of the Defendants’ alleged misrepresentations concerning the safety profile of Merck's pain-killer, VIOXX, was settled shortly before trial and after more than 10 years of litigation, during which time plaintiffs achieved a unanimous and groundbreaking victory for investors at the U.S. Supreme Court. The settlement is the largest securities recovery ever achieved against a pharmaceutical company and among the 15 largest recoveries of all time.
Abe was also a principal member of the trial team that prosecuted In re Schering-Plough Corp./ENHANCE Securities Litigation and In re Merck & Co., Inc. Vytorin/Zetia Securities Litigation, which settled on the eve of trial for a combined $688 million.  This $688 million settlement represents the second largest securities class action recovery against a pharmaceutical company in history and is among the largest securities class action settlements of any kind.
Abe has also obtained several additional significant recoveries on behalf of investors in pharmaceutical and life sciences companies, including a $142 million recovery in Medina v. Clovis Oncology, Inc., a securities fraud class action arising from Defendants’ alleged misstatements about the efficacy and safety of its most important drug; a $55 million recovery in In re HeartWare International, Inc. Securities Litigation, a case arising from Defendants’ alleged misstatements about the device-maker’s compliance with FDA regulations and the performance of its key heart pump; and a $44 million recovery in In re Adeptus Health Inc. Securities Litigation, a case arising from alleged misstatements concerning the liquidity and cash flow of the country's largest operator of freestanding emergency rooms.
Abe secured a $149 million recovery on behalf of investors in Equifax, Inc., helping to lead a securities class action arising from one of the largest data breaches in American history. Abe also played a lead role in securing a $150 million settlement of investors’ claims against JPMorgan Chase arising from alleged misrepresentations concerning the trading activities of the so-called “London Whale.”
He is currently prosecuting In re Cognizant Technology Solutions Corp. Securities Litigation; In re The Boeing Company Aircraft Securities Litigation; Union Asset Management Holding AG v. The Kraft Heinz Company; In re City of Sunrise Firefighters' Pension Fund v. Oracle Corp.; In re Myriad Genetics, Inc. Securities Litigation; and Cambridge Retirement System v. Amneal Pharmaceuticals, Inc., among others.
Prior to joining the firm, Abe represented institutional clients in a number of high-profile securities, corporate governance, and antitrust matters.
Abe was an award-winning member of his law school's national moot court team. Following law school, Abe served as a judicial clerk to Chief Justice Michael L. Bender of the Colorado Supreme Court.
Super Lawyers has regularly selected Abe as a New York “Rising Star” in recognition of his accomplishments, and he was recently named a 2021 "Rising Star" by Law360 and chosen by Benchmark Litigation for its 2021 “40 & Under Hot List.”
David Madigan is the Provost and Senior Vice President for Academic Affairs at Northeastern University. Previously he was Executive Vice President of Arts and Sciences and Dean of the Faculty at Columbia University. Prior to his position at Columbia, he worked for several technology companies and universities, including AT&T Inc., Rutgers University and the University of Washington. Dr. Madigan’s research interests and publications include topics such as Bayesian statistics, text mining, Monte Carlo methods, pharmacovigilance and probabilistic graphical models. He received a bachelor’s degree in Mathematical Sciences and Ph.D. in Statistics from Trinity College Dublin. Dr. Madigan is a Fellow of the American Statistical Association, the Institute of Mathematical Statistics, and the American Association for the Advancement of Science, and has served as Editor-in-Chief of Statistical Science.  Dr. Madigan has testified extensively in litigation related to pharmaceutical produces and medical devices.

Practice Areas: Biotechnology & Life Sciences, Complex Litigation, Healthcare & Pharmaceutical Law, Litigation & Appeals
Online Media Type: Audio
Production Date: 09/30/2021 2:00 PM EDT
Level: Intermediate
Category: Standard
Duration: 2 Hours, 0 Minutes
Online Format: Live

Click here for information on subscription discounts and Group Viewing opportunities.

Purchase of this product provides online access for 180 days. If you are purchasing a live webcast, you will receive complimentary access to the on demand version for 180 days once it becomes available. Please note that the on demand and podcast versions may, or may not be accredited in your state.

If you intend to take a course for CLE credit, please make sure your state is listed in the "Accreditation" section to the upper right of the program description. Accreditation displayed is unique to the purchased program format (live conference, live webcast, on demand, podcast). Credit totals listed for live conferences are the maximum credits available. Credits issued will be based upon actual time in attendance.  Credit totals for other formats are for complete programs.  Partial credit is not available for any online or downloadable format. 


West LegalEdcenter will not provide accreditation for states not listed. 

CLE Scholarship information
Tuition Assistance for legal professionals taking our programs. Learn more about the program.

This product is intended for individual use by the named purchaser. Group viewings for online programs may be arranged for five or more attorneys within the same organization prior to viewing by emailing

People who bought this program also bought:
There are no current recommendations
E-mail a colleague about this program.
Total Credits: 2
Specialty Credits: 
Status: Reciprocal Credit Available
Expiration: 09/29/2022
Training Type: Online

West LegalEdcenter provides accreditation as described here. You may be able to self apply for credits in states not listed.

Check your state requirements and get contact information.
Abe Alexander - Bernstein Litowitz Berger & Grossman LLP
Dr. David Madigan - Northeastern University
This product is designed to provide information in regard to the subject matter covered. It is sold with the understanding that the publisher is not engaged in rendering legal, accounting, or other professional service. If legal advice or other expert assistance is required, the services of a competent professional person should be sought.

Page Disclaimer
No page disclaimer found.
Home |  Search |  CLE Requirements |  Site Map
Content Partners |  Technical Requirements |  Help |  Contact Us
About Us |  Privacy Statement
© 2021 Thomson Reuters